“We are incredibly proud to be recognized with this fine award”, comments Fredrik Alpsten, CEO of Devyser. "We have had strong international growth in recent years, especially in Europe and Asia. Our investment in expanding direct sales in key markets has been highly successful. Now our focus is on the North American market. In June, we will inaugurate our new laboratory in Atlanta, Georgia, and earlier this week we presented a collaboration agreement with Thermo Fisher Scientific, an American company and world leader in the diagnostics industry. Through this partnership Thermo Fisher Scientific will market and sell, under combined brands, Devyser's unique post-transplant follow-up NGS products in the US, Canada, and Europe, which means more patients can access better transplant care".

“The winner is a pioneer in advanced genetic testing, DNA diagnostics. The company is at the forefront of research in one of the areas that has the potential to revolutionize healthcare by enabling to identify and predict diseases early. Through the goal that every patient should receive a correct diagnosis in the shortest possible time, they contribute to a development with a focus on the patient and care provider with regard to sustainability and resources. From the beginning a research company that from the head office in Hägersten developed 29 different products that are now available in 50 countries. With intensive export investments in recent years, they have made a fantastic growth journey with great sales successes, where 92 percent of total sales are made up of export income".

“Partnering with Thermo Fisher, the leading innovator in the HLA industry, is a great opportunity for Devyser and a significant milestone for our company. Through this strategic partnership, clinical labs, clinicians and patients in the US, Canada and Europe will have broad and fast access to Devyser ́s innovative NGS based products for post-transplant monitoring. The agreement is also a quality stamp of our company and our products,” says Fredrik Alpsten, CEO of Devyser.

“We are excited to partner with Devyser. Their post-transplant NGS offerings are unique and highly complementary to our existing, One Lambda–branded products. I’m confident our partnership will support better patient outcomes,” says Nicole Brockway, President, Transplant Diagnostics, Thermo Fisher Scientific.

“Thermo Fisher is very well-established and positioned in both the US and European market, and with their commercial infrastructure and resources, they can cover both US and Europe efficiently. Our sensitive assays and streamlined work process give labs the ability to provide fast and trusted results. Further, the Devyser post-transplant products are pending IVDR certification for the European market. Together, our brands provide a strong proposition to customers and laboratories across the transplantation field. Devyser will continue to grow and focus on product development in the transplant field”, says Theis Kipling, CCO of Devyser.

--We´re proud to announce the launch of our first IVDR product on the market. The launch is proof of our hard work to transition to IVDR, and our long-term commitment to quality and patient safety. To our customers it´s a reassurance that we will continue to provide safe and reliable products. 

Achieving the MDSAP certification confirms our ongoing commitment to maintaining the highest quality assurance standards within the In Vitro Diagnostic Medical Devices (IVD). The certification provides compliance in new jurisdictions enabling great potential for future market expansion and growth.

Delivering products that meet our customers’ high expectations is at the core of our business. The MDSAP certification is yet another token of this commitment, an achievement made possible by the entire Devyser staff and their unwavering focus on quality.

When Covid-19 testing took precedence over all other types of molecular diagnostics thousands of other patients had to wait for their test results, in many cases significantly delaying diagnosis and treatment

Laboratories now face a massive testing debt as ordinary testing is resumed. I am proud that Devyser now offers a game-changing solution for hereditary breast and ovarian cancer diagnostics that enables laboratories to deliver results in just 24 hours, faster than any other product on the market. With hands-on time kept to a minimum, the lab can process large volumes quickly and deliver the critical results without any further delays

Current technologies for measurement of mixed chimerism either have limitations in sensitivity, or lack precision at higher levels of mixed chimerism. In this study we show that assays utilizing the quantitative properties of the NGS technology may replace both current STR and qPCR protocols used in our lab with a single assay combining both high sensitivity and precision throughout the dynamic range of the test

We are very happy to provide routine diagnostics labs with an assay that offers all the advantages of modern technologies in a single test. This solution will relieve laboratories of the burden of labor-intensive and combined complex workflows so that they can really focus on diagnostics.

There is an increasing demand for our prenatal diagnostic products in China. Dahui Biotech’s established distribution and service organization reaches genetic laboratories across China. This, together with their extensive expertise in prenatal diagnostic products, makes Dahui Biotech the ideal distribution partner for our products.

We are excited to offer Devyser’s popular prenatal diagnostic products in China. The products are already in use at several reference laboratories in China and are in demand because of their high quality. They help laboratories speed up analysis time from weeks to hours, thereby improving throughput and reducing parental anxiety through shorter waiting time. This is fully in line with our commitment to always offer the best available technology to our customers.

I extend a warm welcome to Oliver Krause, who brings extensive knowledge and experience of the German, Austrian and Swiss diagnostic markets. He understands the needs of our customers and the specific requirements of the diagnostic lab. Our products are well-known in German-speaking Europe, and with his leadership in our local office, we look forward to continuing our growth

I have always been impressed by Devyser’s commitment to product development based on customer needs, combined with an excellent reputation in the market. This makes us one of the most preferred suppliers of DNA diagnostics.

Devyser is in a very exciting phase, especially with the launch of next-generation sequencing products, and I look forward to representing the company and contributing to our further success

We are very excited to offer NGS technology that has the capacity to revolutionize genetic testing. This solution will relieve laboratories from the burden of labor-intensive and complex workflows so that they can really focus on diagnostics. Our partnership will help continue to reduce the diagnostic turnaround time from days to hours, enabling laboratories to significantly improve their efficiency and cut costs

We are very pleased to broaden the choice of NGS kits supported by Sophia DDM®. Our fast-growing clinical genomics community will be able to leverage Devyser’s reliable and easy-to-use products to obtain clinical grade results on Sophia DDM®. This partnership continues to help laboratories unlock the power of NGS with record-low turnaround time, improving both diagnostics and treatment options for patients